Last reviewed · How we verify
FCN-437c
At a glance
| Generic name | FCN-437c |
|---|---|
| Also known as | Dose-escalation and expansion |
| Sponsor | Ahon Pharmaceutical Co., Ltd. |
| Modality | Small molecule |
| Phase | Phase 1 |
Approved indications
Common side effects
Key clinical trials
- Clinical Trial of FCN-437c Capsule in Patients With Hepatic Insufficiency (PHASE1)
- Clinical Study on Pharmacokinetics of FCN-437c Capsule and Its Effect on QT Interval in Healthy Subjects (PHASE1)
- This is a Multicenter, Randomized, Double-blind, Placebo-controlled Phase III Clinical Study Evaluating the Efficacy and Safety of FCN-437c Versus Placebo in Combination With Letrozole or Anastrozole ± Goserelin in Women With HR+ and HER2- Advanced Breast Cancer. (PHASE3)
- This is a Multicenter, Randomized, Double-blind, Placebo-controlled Phase III Clinical Study Evaluating the Efficacy and Safety of FCN-437c in Combination With Fluvestrant ± Goseraline Versus Placebo Combined With Fulvestrant ± Goserelin in Women With HR+ and HER2- Advanced Breast Cancer. (PHASE3)
- Study of FCN-437c in Patients With Advanced Solid Tumors (PHASE1)
- Study of Efficacy, Safety, and Pharmacokinetics of FCN-437c in Combination With Fulvestrant or Letrozole+Goserelin (PHASE2)
- Safety, Tolerability, Pharmacokinetics and Antitumor Activity of FCN-437c (PHASE1, PHASE2)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- FCN-437c CI brief — competitive landscape report
- FCN-437c updates RSS · CI watch RSS
- Ahon Pharmaceutical Co., Ltd. portfolio CI